Indication: Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.

Insight:

Dosing: The recommended dosage of Rinvoq is 15 mg once daily.
Dosage forms: Extended-release tablets 15 mg and 30 mg.
Adverse events: Adverse reactions (≥ 1%) were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, and acne.
Mechanism of action: JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
Manufacturer: AbbVie

Sources:

Microsoft Word - master-uspi-upadacitinib (rxabbvie.com)

rinvoq image - Google Search